Navigation Links
Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
Date:4/25/2012

ATLANTA, April 25, 2012 /PRNewswire-USNewswire/ -- Given the narrow initial public offering window, declining venture investments and tough capital markets, mergers and acquisitions (M&A) have become the exit of choice for many biopharmaceutical companies. In 2011, there were more M&As than in 2010, deal value was higher, but it still wasn't the flood of deals many industry observers had expected, according to BioWorld.

Another not-so-positive trend for biotech in 2011 was the continued decline in the number of collaborations. A total of 465 licensing or partnership transactions closed last year, compared to 592 in 2010. In 2009, a total of 650 deals got done, as reported in the just-published BioWorld Biotechnology State of the Industry Report 2012.

In the wake of the 2008 recession, many biotech players were left with insufficient cash and depressed values, while cash-rich pharmas have been facing the dreaded patent cliff, creating an environment that appeared ripe for a massive wave of consolidation. Analysts predicted a frenzy of M&As, but BioWorld reports that those predictions have not been borne out.

"The big pharma mega mergers of 2009 tamped down biotech acquisitions that year, and the 'digestion' of those mergers was attributed to the slower-than-expected M&A trends in 2010," said Jennifer Boggs, BioWorld's managing editor. "Hopes were high going into 2011, but the once-again anticipated rush of M&A activity still did not emerge. Acquisition trends in the life sciences space held steady at best."

"2012 may be a different story," said Lynn Yoffee, BioWorld's executive editor. "With four biopharma billion-dollar-plus M&A deals already, the average deal size will undoubtedly increase."

M&A and deals activity are just one section of BioWorld's annual report.

"The BioWorld news team also analyzed financing, scientific and regulatory trends for 2011, putting the information and data in context with what's happening now and going forward in 2012," Yoffee said. "It's a vital resource on key trends designed to guide executives' decision-making as they prep for the next big deal or when strategizing about fundraising. Near-term biopharma sector history is the best guide for smart planning."

BioWorld is the biopharmaceutical industry's most respected news source for more than two decades. For a copy of the BioWorld Biotechnology State of the Industry Report 2012, call (800) 477-6307 or, outside the U.S., (404) 262-5476 or visit www.bioworld.com.


'/>"/>
SOURCE BioWorld
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Equity Research on Most Popular Searches: Atmel, USG, Applied Materials, Sprint Nextel, Galena Biopharma, and Key Energy Services
2. PAREXEL Global Survey Results Identify Top Concerns of Biopharma Industry in Achieving Commercial Success
3. Pharmspective Announces the Release of ClearView™ - a New Health Care Reform Knowledge Management Web Application for the Biopharma Industry
4. PDL BioPharma Announces Conversion Rate Adjustments for Its Convertible Notes
5. Medtrack One View - A New More Powerful Biopharmaceutical Intelligence Tool Is Now Available
6. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2011 Financial Results
7. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year-End 2011 Financial Results
8. Innovative School of BioPharmacy to Open in Fall 2014
9. The Centers for Disease Control & Prevention Signs Vaccine Warehouse and Distribution Contract with Sentry BioPharma Services
10. PDL BioPharma to Announce Fourth Quarter and Full Year 2011 Financial Results on February 23, 2012
11. Top 200 Biopharmaceuticals Industry Report (Global)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment is ... period The Cardiology Devices segment is likely to ... 15 Mn in 2018 over 2017. By the end of ... valuation close to US$ 700 Mn, expanding at a CAGR ... dominated the Asia Pacific reprocessed medical ...
(Date:4/19/2017)... , April 19, 2017  Vanderbilt University Medical ... patients in Nashville , Tennesse have ... Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. The ... provide long-term reflux control by restoring normal function to ... 65 million people in the United States ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
Breaking Medicine Technology:
(Date:4/25/2017)... Vegas, NV (PRWEB) , ... April 25, 2017 ... ... can now choose a modern procedure that achieves results in a fraction of ... in Las Vegas, NV, with Significance Dental Specialists, now offers this revolutionary ...
(Date:4/25/2017)... GA (PRWEB) , ... April 25, 2017 , ... ... their neck and back pain with a reputable physician in their area, announces the ... CRM protects patient information for patients who are looking for reputable physicians to help ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a ... its patient care management module. Using this new feature, sleep physicians can now ... initiated on continuous positive airway pressure (CPAP), oral, or other forms of sleep ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG ... Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national ... which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit ...
Breaking Medicine News(10 mins):